IgA nephropathy (IgAN) is an autoimmune disease in which poorly galactosylated IgA1 is the antigen recognized by naturally occurring anti-glycan antibodies, leading to formation of nephritogenic circulating immune complexes. Incidence of IgAN displays geographical and racial disparity: common in Europe, North America, Australia, and east Asia, uncommon in African Americans, many Asian and South American countries, Australian Aborigines, and rare in central Africa. In analyses of sera and cells from White IgAN patients, healthy controls, and African Americans, IgAN patients exhibited substantial enrichment for IgA-expressing B cells infected with Epstein-Barr virus (EBV), leading to enhanced production of poorly galactosylated IgA1. Disparities in incidence of IgAN may reflect a previously disregarded difference in the maturation of the IgA system as related to the timing of EBV infection. Compared with populations with higher incidences of IgAN, African Americans, African Blacks, and Australian Aborigines are more frequently infected with EBV during the first 1-2 years of life at the time of naturally occurring IgA deficiency when IgA cells are less numerous than in late childhood or adolescence. Therefore, in very young children EBV enters "non-IgA" cells. Ensuing immune responses prevent infection of IgA B cells during later exposure to EBV at older ages. Our data implicate EBV-infected cells as the source of poorly galactosylated IgA1 in circulating immune complexes and glomerular deposits in patients with IgAN. Thus, temporal differences in EBV primo-infection as related to naturally delayed maturation of the IgA system may contribute to geographic and racial variations in incidence of IgAN.

Department of Immunology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Department of Medicine University of Alabama at Birmingham Birmingham AL United States

Department of Microbiology University of Alabama at Birmingham Birmingham AL United States

Laboratory of Cellular and Molecular Immunology Institute of Microbiology Czech Academy of Sciences Prague Czechia

Zobrazit více v PubMed

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med (2013) 368:2402–14. doi: 10.1056/NEJMra1206793 PubMed DOI

Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, et al. . IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol (2013) 8:217–40. doi: 10.1146/annurev-pathol-011110-130216 PubMed DOI

Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, et al. . The origin and activities of IgA1-containing immune complexes in IgA nephropathy. Front Immunol (2016) 7:117. doi: 10.3389/fimmu.2016.00117 PubMed DOI PMC

Robert T, Berthelot L, Cambier A, Rondeau E, Monteiro RC. Molecular insights into the pathogenesis of IgA nephropathy. Trends Mol Med (2015) 21:762–75. doi: 10.1016/j.molmed.2015.10.003 PubMed DOI

Zhang C, Zeng XH, Li ZX, Wang Z, Li SM. Immunoglobulin A nephropathy: current progress and future directions. Transl Res (2015) 166:134–44. doi: 10.1016/j.trsl.2015.02.007 PubMed DOI

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. . The pathophysiology of IgA nephropathy. J Am Soc Nephrol (2011) 22:1795–803. doi: 10.1681/ASN.2011050464 PubMed DOI PMC

Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol (1993) 104:172–82. doi: 10.1159/000422410 PubMed DOI

Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, et al. . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int (2001) 59:1077–85. doi: 10.1046/j.1523-1755.2001.0590031077.x PubMed DOI

Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J. Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transpl (1993) 8:25–8. doi: 10.1093/oxfordjournals.ndt.a092266 PubMed DOI

Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, et al. . Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest (1986) 77:1931–8. doi: 10.1172/JCI112522 PubMed DOI PMC

Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest (1980) 66:1432–6. doi: 10.1172/JCI109998 PubMed DOI PMC

Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int (2001) 60:969–73. doi: 10.1046/j.1523-1755.2001.060003969.x PubMed DOI

Allen AC. Abnormal glycosylation of IgA: is it related to the pathogenesis of IgA nephropathy? Nephrol Dial Transpl (1995) 10:1121–4. doi: 10.1093/ndt/10.7.1121 PubMed DOI

Hiki Y, Kokubo T, Iwase H, Masaki Y, Sano T, Tanaka A, et al. . Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. J Am Soc Nephrol (1999) 10:760–9. doi: 10.1681/ASN.V104760 PubMed DOI

Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int (2004) 65:1544–7. doi: 10.1111/j.1523-1755.2004.05407 PubMed DOI

Xu LX, Zhao MH. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int (2005) 68:167–72. doi: 10.1111/j.1523-1755.2005.00390.x PubMed DOI

Lau KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, et al. . Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol (2007) 22:2067–72. doi: 10.1007/s00467-007-0623-y PubMed DOI

Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. . IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest (2008) 118:629–39. doi: 10.1172/JCI33189 PubMed DOI PMC

Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. . Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int (2007) 71:1148–54. doi: 10.1038/sj.ki.5002185 PubMed DOI

Oortwijn BD, Roos A, Royle L, van Gijlswijk-Janssen DJ, Faber-Krol MC, Eijgenraam JW, et al. . Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol (2006) 17:3529–39. doi: 10.1681/ASN.2006040388 PubMed DOI

Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int (1997) 52:509–16. doi: 10.1038/ki.1997.361 PubMed DOI

Monteiro RC, Halbwachs-Mecarelli L, Roque-Barreira MC, Noel LH, Berger J, Lesavre P. Charge and size of mesangial IgA in IgA nephropathy. Kidney Int (1985) 28:666–71. doi: 10.1038/ki.1985.181 PubMed DOI

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. . Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest (2009) 119:1668–77. doi: 10.1172/JCI38468 PubMed DOI PMC

Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. . Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol (2012) 23:1579–87. doi: 10.1681/ASN.2012010053 PubMed DOI PMC

Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, et al. . IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int (2005) 67:504–13. doi: 10.1111/j.1523-1755.2005.67107.x PubMed DOI

Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, et al. . In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol (2012) 2:166–72. doi: 10.1016/j.rinim.2012.08.002 PubMed DOI PMC

Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, et al. . Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun (2021) 118:102593. doi: 10.1016/j.jaut.2021.102593 PubMed DOI PMC

Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis (1988) 12:340–7. doi: 10.1016/S0272-6386(88)80021-0 PubMed DOI

Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol (2018) 38:435–42. doi: 10.1016/j.semnephrol.2018.05.013 PubMed DOI

Zhang H, Barratt J. Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol (2021) 43:707–15. doi: 10.1007/s00281-021-00884-7 PubMed DOI

Habib MA, Badruddoza SM. Pattern of glomerular diseases among adults in Rajshahi, the northern region of Bangladesh. Saudi J Kidney Dis Transpl (2012) 23:876–80. doi: 10.4103/1319-2442.98195 PubMed DOI

Jennette JC, Wall SD, Wilkman AS. Low incidence of IgA nephropathy in blacks. Kidney Int (1985) 28:944–50. doi: 10.1038/ki.1985.222 PubMed DOI

McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl (2011) 26:414–30. doi: 10.1093/ndt/gfq665 PubMed DOI

Neelakantappa K, Gallo GR, Baldwin DS. Immunoglobulin A nephropathy in blacks and homozygosity for the genetic marker A2m. Ann Intern Med (1986) 104:287–8. doi: 10.7326/0003-4819-104-2-287_2 PubMed DOI

Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int (2006) 69:1455–8. doi: 10.1038/sj.ki.5000292 PubMed DOI

Hoy WE, Samuel T, Mott SA, Kincaid-Smith PS, Fogo AB, Dowling JP, et al. . Renal biopsy findings among indigenous australians: a nationwide review. Kidney Int (2012) 82:1321–31. doi: 10.1038/ki.2012.307 PubMed DOI

Galla JH, Kohaut EC, Alexander R, Mestecky J. Racial difference in the prevalence of IgA-associated nephropathies. Lancet (1984) 2:522. doi: 10.1016/S0140-6736(84)92599-6 PubMed DOI

Crowley-Nowick PA, Julian BA, Wyatt RJ, Galla JH, Wall BM, Warnock DG, et al. . IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int (1991) 39:1218–24. doi: 10.1038/ki.1991.154 PubMed DOI

Hastings MC, Moldoveanu Z, Julian BA, Novak J, Sanders JT, McGlothan KR, et al. . Galactose-deficient IgA1 in African americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol (2010) 5:2069–74. doi: 10.2215/CJN.03270410 PubMed DOI PMC

Seedat YK, Nathoo BC, Parag KB, Naiker IP, Ramsaroop R. IgA nephropathy in blacks and indians of Natal. Nephron (1988) 50:137–41. doi: 10.1159/000185144 PubMed DOI

McCoy RC, Abramowsky CR, Tisher CC. IgA nephropathy. Am J Pathol (1974) 76:123–44. PubMed PMC

Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest (2014) 124:2325–32. doi: 10.1172/JCI74475 PubMed DOI PMC

Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. . Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int (2011) 80:79–87. doi: 10.1038/ki.2011.16 PubMed DOI PMC

Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al. . IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet (2000) 26:354–7. doi: 10.1038/81677 PubMed DOI

Lin X, Ding J, Zhu L, Shi S, Jiang L, Zhao M, et al. . Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transpl (2009) 24:3372–5. doi: 10.1093/ndt/gfp294 PubMed DOI

Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. . Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol (2008) 19:1008–14. doi: 10.1681/ASN.2007091052 PubMed DOI PMC

Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, et al. . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet (2014) 46:1187–96. doi: 10.1038/ng.3118 PubMed DOI PMC

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, et al. . Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PloS Genet (2012) 8:e1002765. doi: 10.1371/journal.pgen.1002765 PubMed DOI PMC

Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, et al. . GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PloS Genet (2017) 13:e1006609. doi: 10.1371/journal.pgen.1006609 PubMed DOI PMC

Zachova K, Kosztyu P, Zadrazil J, Matousovic K, Vondrak K, Hubacek P, et al. . Role of Epstein-Barr virus in pathogenesis and racial distribution of IgA nephropathy. Front Immunol (2020) 11:267. doi: 10.3389/fimmu.2020.00267 PubMed DOI PMC

Kutteh WH, Koopman WJ, Conley ME, Egan ML, Mestecky J. Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens. J Exp Med (1980) 152:1424–9. doi: 10.1084/jem.152.5.1424 PubMed DOI PMC

Kubagawa H, Burrows PD, Grossi CE, Mestecky J, Cooper MD. Precursor B cells transformed by Epstein-Barr virus undergo sterile plasma-cell differentiation: J-chain expression without immunoglobulin. Proc Natl Acad Sci USA (1988) 85:875–9. doi: 10.1073/pnas.85.3.875 PubMed DOI PMC

Conley ME, Koopman WJ. In vitro regulation of IgA subclass synthesis. i. discordance between plasma cell production and antibody secretion. J Exp Med (1982) 156:1615–21. doi: 10.1084/jem.156.6.1615 PubMed DOI PMC

Conley ME, Chan MA, Sigal NH. In vitro regulation of IgA subclass production. III. selective transformation of IgA1 producing cells by Epstein-Barr virus. J Immunol (1987) 138:1403–7. doi: 10.4049/jimmunol.138.5.1403 PubMed DOI

Moldoveanu Z, Egan ML, Mestecky J. Cellular origins of human polymeric and monomeric IgA: intracellular and secreted forms of IgA. J Immunol (1984) 133:3156–62. doi: 10.4049/jimmunol.133.6.3156 PubMed DOI

Ehlin-Henriksson B, Zou JZ, Klein G, Ernberg I. Epstein-Barr Virus genomes are found predominantly in IgA-positive B cells in the blood of healthy carriers. Int J Cancer (1999) 83:50–4. doi: 10.1002/(SICI)1097-0215(19990924)83:1<50::AID-IJC10>3.0.CO;2-1 PubMed DOI

Mestecky J, Waldo FB, Britt WJ, Julian BA, Tomana M, van den Wall Bake AWL, et al. . Exogenous antigens deposited in the glomeruli of patients with IgA nephropathy. In: Sakai H, Sakai O, Nomoto Y, editors. Pathogenesis of IgA nephropathy. Tokyo, Japan: Harcourt Brace Jovanovich; (1990). p. 247–57.

Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol (1986) 6:74–86. doi: 10.1007/BF00915367 PubMed DOI

Jackson S, Moldoveanu Z, Kirk KA, Julian BA, Patterson TF, Mullins AL, et al. . IgA-containing immune complexes after challenge with food antigens in patients with IgA nephropathy. Clin Exp Immunol (1992) 89:315–20. doi: 10.1111/j.1365-2249.1992.tb06952.x PubMed DOI PMC

Soylu A, Kasap B, Soylu OB, Turkmen M, Kavukcu S. Does feeding in infancy effect the development of IgA nephropathy? Pediatr Nephrol (2007) 22:1040–4. doi: 10.1007/s00467-007-0433-2 PubMed DOI

Cambier A, Gleeson PJ, Abbad L, Canesi F, da Silva J, Bex-Coudrat J, et al. . Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy. Kidney Int (2022) 101:274–87. doi: 10.1016/j.kint.2021.09.023 PubMed DOI

Woof JM, Mestecky J. Mucosal immunoglobulins. In: Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. 1, 4 ed. Amsterdam: Academic Press; (2015). p. 287–323.

Novak J, Tomana M, Kilian M, Coward L, Kulhavy R, Barnes S, et al. . Heterogeneity of O-glycosylation in the hinge region of human IgA1. Mol Immunol (2000) 37:1047–456. doi: 10.1016/S0161-5890(01)00019-0 PubMed DOI

Novak J, Barratt J, Julian BA, Renfrow MB. Aberrant glycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol (2018) 38:461–76. doi: 10.1016/j.semnephrol.2018.05.016 PubMed DOI PMC

Ohyama Y, Renfrow MB, Novak J, Takahashi K. Aberrantly glycosylated IgA1 in IgA nephropathy: What we know and what we don't know. J Clin Med (2021) 10:3467. doi: 10.3390/jcm10163467 PubMed DOI PMC

Mestecky J, Kulhavy R, Tomana M, Brown R, Kilian M, Paulsen K, et al. . (2004). Localization of antigenic determinants on galactose-deficient IgA1 recognized by IgG antibodies, in: 10th International Symposium on IgA Nephropathy, St Ettienne, France, March 26-27 10th International Symposium on IgA Nephropathy (St Ettienne, France: www.igan-world.org). p. 59, Abstr. #403.

Conley ME, Delacroix DL. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense? Ann Intern Med (1987) 106:892–9. doi: 10.7326/0003-4819-106-6-892 PubMed DOI

Leung JCK, Poon PYK, Lai KN. Increased sialylation of polymeric immunoglobulin A1: Mechanism of selective glomerular deposition in immunoglobulin A nephropathy? J Lab Clin Med (1999) 133:152–60. doi: 10.1016/S0022-2143(99)90008-2 PubMed DOI

Crago SS, Kutteh WH, Moro I, Allansmith MR, Radl J, Haaijman JJ, et al. . Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. J Immunol (1984) 132:16–8. doi: 10.4049/jimmunol.132.1.16 PubMed DOI

Brandtzaeg P. The mucosal B cell system. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. I, 4 ed. Amsterdam: Academic Press; (2015). p. 623–81.

Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol (2012) 34:365–82. doi: 10.1007/s00281-012-0306-z PubMed DOI

Stuchlova Horynova M, Raska M, Clausen H, Novak J. Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci (2013) 70:829–39. doi: 10.1007/s00018-012-1082-6 PubMed DOI PMC

Iwasaki H, Zhang Y, Tachibana K, Gotoh M, Kikuchi N, Kwon YD, et al. . Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2. J Biol Chem (2003) 278:5613–21. doi: 10.1074/jbc.M211097200 PubMed DOI

Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, et al. . Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol (2007) 369:69–78. doi: 10.1016/j.jmb.2007.03.002 PubMed DOI PMC

Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, et al. . Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem (2014) 289:5330–9. doi: 10.1074/jbc.M113.512277 PubMed DOI PMC

Narita I, Gejyo F. Pathogenetic significance of aberrant glycosylation of IgA1 in IgA nephropathy. Clin Exp Nephrol (2008) 12:332–8. doi: 10.1007/s10157-008-0054-5 PubMed DOI

Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest (1999) 104:73–81. doi: 10.1172/JCI5535 PubMed DOI PMC

Valentijn RM, Radl J, Haaijman JJ, Vermeer BJ, Weening JJ, Kauffmann RH, et al. . Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy. Kidney Int (1984) 26:760–6. doi: 10.1038/ki.1984.213 PubMed DOI

Bene MC, Faure G, Duheille J. IgA nephropathy: characterization of the polymeric nature of mesangial deposits by in vitro binding of free secretory component. Clin Exp Immunol (1982) 47:527–34. PubMed PMC

Tomino Y, Sakai H, Miura M, Endoh M, Nomoto Y. Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. Clin Exp Immunol (1982) 49:419–25. PubMed PMC

Kokubo T, Hiki Y, Iwase H, Tanaka A, Nishikido J, Hotta K, et al. . Exposed peptide core of IgA1 hinge region in IgA nephropathy. Nephrol Dial Transpl (1999) 14:81–5. doi: 10.1093/ndt/14.1.81 PubMed DOI

Kokubo T, Hashizume K, Iwase H, Arai K, Tanaka A, Toma K, et al. . Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transpl (2000) 15:28–33. doi: 10.1093/ndt/15.1.28 PubMed DOI

Nakamura I, Iwase H, Arai K, Nagai Y, Toma K, Katsumata T, et al. . Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes. Nephrology (2004) 9:26–30. doi: 10.1111/j.1440-1797.2003.00225.x PubMed DOI

Jackson S, Montgomery RI, Mestecky J, Czerkinsky C. Normal human sera contain antibodies directed at fab of IgA. J Immunol (1987) 138:2244–8. doi: 10.4049/jimmunol.138.7.2244 PubMed DOI

Jackson S, Montgomery RI, Mestecky J, Julian BA, Galla JH, Czerkinsky C. Antibodies directed at fab of IgA in the sera of normal individuals and IgA nephropathy patients. Adv Exp Med Biol (1987) 216B:1537–44. PubMed

Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, et al. . Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy. J Am Soc Nephrol (2016) 27:3278–84. doi: 10.1681/ASN.2014101044 PubMed DOI PMC

Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, et al. . Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. J Am Soc Nephrol (2019) 30:2017–26. doi: 10.1681/ASN.2018111156 PubMed DOI PMC

Serafini-Cessi F, Malagolini N, Nanni M, Dall'Olio F, Campadelli-Fiume G, Tanner J, et al. . Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. Virology (1989) 170:1–10. doi: 10.1016/0042-6822(89)90345-0 PubMed DOI

Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, et al. . Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol (2006) 13:996–1001. doi: 10.1038/nsmb1161 PubMed DOI

Kieff E. Epstein-Barr Virus and its replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven; (1996). p. 2343–96.

Wertz GW, Krieger M, Ball LA. Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O-glycosylation. J Virol (1989) 63:4767–76. doi: 10.1128/jvi.63.11.4767-4776.1989 PubMed DOI PMC

Johnson DC, Spear PG. O-linked oligosaccharides are acquired by herpes simplex glycoproteins in the Golgi apparatus. Cell (1983) 32:987–97. doi: 10.1016/0092-8674(83)90083-1 PubMed DOI PMC

Cisar JO, Sandberg AL, Reddy GP, Abeygunawardana C, Bush CA. Structural and antigenic types of cell wall polysaccharides from viridans group streptococci with receptors for oral actinomyces and streptococcal lectins. Infect Immun (1997) 65:5035–41. doi: 10.1128/iai.65.12.5035-5041.1997 PubMed DOI PMC

Zikan J, Mestecky J, Schrohenloher RE, Tomana M, Kulhavy R. Studies on human secretory immunoglobulin A. V. trypsin hydrolysis at elevated temperatures. Immunochemistry (1972) 9:1185–93. doi: 10.1016/0019-2791(72)90292-3 PubMed DOI

Kaetzel CS, Russell MW. Phylogeny and comparative physiology of mucosal immunoglobulins. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. 1, 4 ed. Amsterdam: Academic Press; (2015). p. 325–47.

Mestecky J, Russell MW. IgA subclasses. Monogr Allergy (1986) 19:277–301. PubMed

Kilian M, Russell MW. Microbial evasion of IgA functions. In: Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. 1, 4 ed. Amsterdam: Academic Press; (2015). p. 455–69.

Brown TA, Mestecky J. Subclass distribution of IgA antibodies to microbial and viral antigens. In: Strober W, Lamm ME, McGhee JR, James SP, editors. Mucosal immunity and infections at mucosal surfaces. New York: Oxford University Press; (1988). p. 340–5.

Endo T, Mestecky J, Kulhavy R, Kobata A. Carbohydrate heterogeneity of human myeloma proteins of the IgA1 and IgA2 subclasses. Mol Immunol (1994) 31:1415–22. doi: 10.1016/0161-5890(94)90157-0 PubMed DOI

Sun Z, Almogren A, Furtado PB, Chowdhury B, Kerr MA, Perkins SJ. Semi-extended solution structure of human myeloma immunoglobulin D determined by constrained X-ray scattering. J Mol Biol (2005) 353:155–73. doi: 10.1016/j.jmb.2005.07.072 PubMed DOI

Zachova K, Jemelkova J, Kosztyu P, Ohyama Y, Takahashi K, Zadrazil J, et al. . Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors. J Am Soc Nephrol (2022) 33:908–17. doi: 10.1681/ASN.2021081086 PubMed DOI PMC

Lai KN, Chui SH, Lai FM, Lam CW. Predominant synthesis of IgA with lambda light chain in IgA nephropathy. Kidney Int (1988) 33:584–9. doi: 10.1038/ki.1988.37 PubMed DOI

Chui SH, Lam CW, Lewis WH, Lai KN. Light-chain ratio of serum IgA1 in IgA nephropathy. J Clin Immunol (1991) 11:219–23. doi: 10.1007/BF00917428 PubMed DOI

Chen N, Nusbaum P, Halbwachs-Mecarelli L, Lesavre P. Light-chain composition of serum IgA1 and in vitro IgA1 production in IgA nephropathy. Nephrol Dial Transpl (1991) 6:846–50. doi: 10.1093/ndt/6.11.846 PubMed DOI

Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis (1988) 12:348–52. doi: 10.1016/S0272-6386(88)80022-2 PubMed DOI

Lai KN, Chan KW, Mac-Moune F, Ho CP, Yan KW, Lam CW, et al. . The immunochemical characterization of the light chains in the mesangial IgA deposits in IgA nephropathy. Am J Clin Pathol (1986) 85:548–51. doi: 10.1093/ajcp/85.5.548 PubMed DOI

Lai KN, Lai FM, Lo ST, Lam CW. Light chain composition of IgA in IgA nephropathy. Am J Kidney Dis (1988) 11:425–9. doi: 10.1016/S0272-6386(88)80056-8 PubMed DOI

Lai KN, To WY, Li PK, Leung JC. Increased binding of polymeric λ-IgA to cultured human mesangial cells in IgA nephropathy. Kidney Int (1996) 49:839–45. doi: 10.1038/ki.1996.116 PubMed DOI

Mestecky J, Tomana M, Zikan J, Moldoveanu Z, Moro I, Komiyama K, et al. . Life history of human IgA: The role of receptors in its distribution and catabolism. In: Tsuchiya M, Nagura H, Hibi T, Moro I, editors. Frontiers of mucosal immunology. Amsterdam: Elsevier Scientific Publishers; (1991). p. 3–12. van del valExcerpta Medica. 1.

Moldoveanu Z, Moro I, Radl J, Thorpe SR, Komiyama K, Mestecky J. Site of catabolism of autologous and heterologous IgA in non-human primates. Scand J Immunol (1990) 32:577–83. doi: 10.1111/j.1365-3083.1990.tb03199.x PubMed DOI

Kutteh WH, Prince SJ, Mestecky J. Tissue origins of human polymeric and monomeric IgA. J Immunol (1982) 128:990–5. doi: 10.4049/jimmunol.128.2.990 PubMed DOI

Conley ME, Bartelt MS. In vitro regulation of IgA subclass synthesis. II. the source of IgA2 plasma cells. J Immunol (1984) 133:2312–6. doi: 10.4049/jimmunol.133.5.2312 PubMed DOI

Landsverk OJ, Snir O, Casado RB, Richter L, Mold JE, Reu P, et al. . Antibody-secreting plasma cells persist for decades in human intestine. J Exp Med (2017) 214:309–17. doi: 10.1084/jem.20161590 PubMed DOI PMC

Baker K, Blumberg RS, Kaetzel CS. Immunoglobulin transport and immunoglobulin receptors. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology, 4 ed. Amsterdam: Elsevier Academic Press; (2015). p. 349–407.

Uffelman JA, Engelhard WE, Jolliff CR. Quantitation of immunoglobulins in normal children. Clin Chim Acta (1970) 28:185–92. doi: 10.1016/0009-8981(70)90178-6 PubMed DOI

West CD, Hong R, Holland NH. Immunoglobulin levels from the newborn period to adulthood and in immunoglobulin deficiency states. J Clin Invest (1962) 41:2054–64. doi: 10.1172/JCI104663 PubMed DOI PMC

Stoop JW, Zegers BJ, Sander PC, Ballieux RE. Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol (1969) 4:101–12. PubMed PMC

Johansson SG, Berg T. Immunoglobulin levels in healthy children. Acta Paediatr Scand (1967) 56:572–9. doi: 10.1111/j.1651-2227.1967.tb15982.x PubMed DOI

Buckley CE, 3rd, Dorsey FC. Serum immunoglobulin levels throughout the life-span of healthy man. Ann Intern Med (1971) 75:673–82. doi: 10.7326/0003-4819-75-5-673 PubMed DOI

Allansmith M, McClellan BH, Butterworth M, Maloney JR. The development of immunoglobulin levels in man. J Pediatr (1968) 72:276–90. doi: 10.1016/s0022-3476(68)80324-5 PubMed DOI

Gleeson M, Cripps AW. Ontogeny of mucosal immunity and aging. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. 1, 4 ed. Amsterdam: Academic Press; (2015). p. 161–85.

El Kaissouni J, Bene MC, Thionnois S, Monin P, Vidailhet M, Faure GC. Maturation of B cells in the lamina propria of human gut and bronchi in the first months of human life. Dev Immunol (1998) 5:153–9. doi: 10.1155/1998/42138 PubMed DOI PMC

Perkkio M, Savilahti E. Time of appearance of immunoglobulin-containing cells in the mucosa of the neonatal intestine. Pediatr Res (1980) 14:953–5. doi: 10.1203/00006450-198008000-00012 PubMed DOI

Buckley RH, Dees SC, O'Fallon WM. Serum immunoglobulins. i. levels in normal children and in uncomplicated childhood allergy. Pediatrics (1968) 41:600–11. doi: 10.1542/peds.41.3.600 PubMed DOI

Fulginiti VA, Sieber OF, Jr., Claman HN, Merrill D. Serum immunoglobulin measurement during the first year of life and in immunoglobulin-deficiency states. J Pediatr (1966) 68:723–30. doi: 10.1016/s0022-3476(66)80444-4 PubMed DOI

Hacsek G, Ormala T, Rintala R, Savilahti E. B cell development in lamina propria of the large intestine: influence of age and T cell densities. APMIS (1999) 107:661–6. doi: 10.1111/j.1699-0463.1999.tb01456.x PubMed DOI

Gustafson CE, Higbee D, Yeckes AR, Wilson CC, De Zoeten EF, Jedlicka P, et al. . Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy. Mucosal Immunol (2014) 7:467–77. doi: 10.1038/mi.2013.64 PubMed DOI PMC

Cerutti A. The regulation of IgA class switching. Nat Rev Immunol (2008) 8:421–34. doi: 10.1038/nri2322 PubMed DOI PMC

Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med (1992) 175:671–82. doi: 10.1084/jem.175.3.671 PubMed DOI PMC

Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, et al. . B cell receptor signal strength determines B cell fate. Nat Immunol (2004) 5:317–27. doi: 10.1038/ni1036 PubMed DOI

Suzuki K, Maruya M, Kawamoto S, Sitnik K, Kitamura H, Agace WW, et al. . The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity (2010) 33:71–83. doi: 10.1016/j.immuni.2010.07.003 PubMed DOI

Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, et al. . A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity (2009) 30:120–9. doi: 10.1016/j.immuni.2008.11.008 PubMed DOI PMC

Bunker JJ, Bendelac A. IgA responses to microbiota. Immunity (2018) 49:211–24. doi: 10.1016/j.immuni.2018.08.011 PubMed DOI PMC

Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, Matsushita M, et al. . Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature (2007) 448:929–33. doi: 10.1038/nature06033 PubMed DOI

McGhee JR, Mestecky J, Elson CO, Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol (1989) 9:175–99. doi: 10.1007/BF00916814 PubMed DOI

Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. . Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA (1992) 89:1890–3. doi: 10.1073/pnas.89.5.1890 PubMed DOI PMC

Hornef MW, Bein G, Wilhelm D, Fricke L, Kirchner H. ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation. Clin Diagn Lab Immunol (1997) 4:545–9. doi: 10.1128/cdli.4.5.545-549.1997 PubMed DOI PMC

Li ZY, Wang CL, Liu LP, Wang H, Lv L, Wang R. Association between interleukin-10 gene polymorphism and development of IgA nephropathy in a Chinese population. Int J Clin Exp Pathol (2016) 9:8663–8.

Zhang Z, Wang H, Zhang L, Crew R, Zhang N, Liu X, et al. . Serum levels of soluble ST2 and IL-10 are associated with disease severity in patients with IgA nephropathy. J Immunol Res (2016) 2016:6540937. doi: 10.1155/2016/6540937 PubMed DOI PMC

Burdin N, Peronne C, Banchereau J, Rousset F. Epstein-Barr Virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med (1993) 177:295–304. doi: 10.1084/jem.177.2.295 PubMed DOI PMC

Thorley-Lawson DA. EBV persistence–introducing the virus. Curr Top Microbiol Immunol (2015) 390:151–209. doi: 10.1007/978-3-319-22822-8_8 PubMed DOI PMC

Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo . Immunity (1998) 9:395–404. doi: 10.1016/s1074-7613(00)80622-6 PubMed DOI

Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo . J Virol (2005) 79:1296–307. doi: 10.1128/JVI.79.2.1296-1307.2005 PubMed DOI PMC

Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity (2002) 16:745–54. doi: 10.1016/s1074-7613(02)00318-7 PubMed DOI

Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PloS Pathog (2012) 8:e1002704. doi: 10.1371/journal.ppat.1002704 PubMed DOI PMC

Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol (2004) 22:929–79. doi: 10.1146/annurev.immunol.22.012703.104622 PubMed DOI

Conley ME, Brown P. IgA subclass distribution in peripheral blood lymphocyte cultures stimulated with lipopolysaccharide, pokeweed mitogen or Epstein-Barr virus. Adv Exp Med Biol (1987) 216B:1185–91. PubMed

Mestecky J, Winchester RJ, Hoffman T, Kunkel HG. Parallel synthesis of immunoglobulins and J chain in pokeweed mitogen-stimulated normal cells and in lymphoblastoid cell lines. J Exp Med (1977) 145:760–5. doi: 10.1084/jem.145.3.760 PubMed DOI PMC

McGhee JR, Beagley KW, Eldridge JH, Fujihashi K, Lue C, Moldoveanu Z, et al. . Interleukin cascade for the regulation of IgA synthesis and immune responses. Protides Biol Fluids (1989) 36:183–91. doi: 10.1016/B978-0-08-037378-2.50030-9 DOI

Fujihashi K, McGhee JR, Lue C, Beagley KW, Taga T, Hirano T, et al. . Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis. J Clin Invest (1991) 88:248–52. doi: 10.1172/JCI115284 PubMed DOI PMC

van den Wall Bake AW, Crowley-Nowick PA, Kulhavy R, Hermans J, Jackson S, Julian BA, et al. . Cytokine-induced immunoglobulin production in primary IgA nephropathy. Am J Kidney Dis (1992) 20:611–7. doi: 10.1016/S0272-6386(12)70228-7 PubMed DOI

Dotz V, Visconti A, Lomax-Browne HJ, Clerc F, Hipgrave Ederveen AL, Medjeral-Thomas NR, et al. . O- and N-glycosylation of serum immunoglobulin a is associated with IgA nephropathy and glomerular function. J Am Soc Nephrol (2021) 32:2455–65. doi: 10.1681/ASN.2020081208 PubMed DOI PMC

Nakayama T, Fujisawa R, Izawa D, Hieshima K, Takada K, Yoshie O. Human B cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CXCR4 and CXCR5. J Virol (2002) 76:3072–7. doi: 10.1128/JVI.76.6.3072-3077.2002 PubMed DOI PMC

Rincon J, Prieto J, Patarroyo M. Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and burkitt's lymphoma cells. Int J Cancer (1992) 51:452–8. doi: 10.1002/ijc.2910510319 PubMed DOI

Cummins JE, Jr., Bunn WJ, Hall SD, Donze HH, Mestecky J, Jackson S. In vitro exposure to highly cytopathic HIV-1 X4 strains increases expression of mucosa-associated integrins on CD4+ T cells. Virology (2001) 280:262–72. doi: 10.1006/viro.2000.0781 PubMed DOI

Delecluse S, Tsai MH, Shumilov A, Bencun M, Arrow S, Beshirova A, et al. . Epstein-Barr Virus induces expression of the LPAM-1 integrin in B cells in vitro and in vivo . J Virol (2019) 93:e01618–18. doi: 10.1128/JVI.01618-18 PubMed DOI PMC

Thorley-Lawson DA. Epstein-Barr Virus: exploiting the immune system. Nat Rev Immunol (2001) 1:75–82. doi: 10.1038/35095584 PubMed DOI

Young LS. Epstein-Barr Virus (Herpesviridae). In: Granoff A, Webster RG, editors. Encyclopedia of virology, 2 ed. San Diego: Academic Press; (1999). p. 487–501.

Rowe M. Epstein-Barr Virus, infection and immunity. In: Delves PJ, Roitt IM, editors. Encyclopedia of immunology. San Diego: Academic Press; (1988). p. 828–33.

Linde A. Epstein-Barr Virus. In: Murray PR, Baron EJ, Jorgensen MA, Pfaller RH, editors. Manual of clinical microbiology. 2, 8 ed. Washington D.C: ASM Press; (2003). p. 1331–40.

Cohen JI. Epstein-Barr Virus infection. N Engl J Med (2000) 343:481–92. doi: 10.1056/NEJM200008173430707 PubMed DOI

Perry M, Whyte A. Immunology of the tonsils. Immunol Today (1998) 19:414–21. doi: 10.1016/s0167-5699(98)01307-3 PubMed DOI

van den Wall Bake AW, Daha MR, Evers-Schouten J, van Es LA. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis (1988) 12:410–4. doi: 10.1016/S0272-6386(88)80036-2 PubMed DOI

Harper SJ, Allen AC, Pringle JH, Feehally J. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol (1996) 49:38–42. doi: 10.1136/jcp.49.1.38 PubMed DOI PMC

Floege J, Feehally J. The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol (2016) 12:147–56. doi: 10.1038/nrneph.2015.208 PubMed DOI

Biggar RJ, Henle G, Bocker J, Lennette ET, Fleisher G, Henle W. Primary Epstein-Barr virus infections in African infants. II. clinical and serological observations during seroconversion. Int J Cancer (1978) 22:244–50. doi: 10.1002/ijc.2910220305 PubMed DOI

Biggar RJ, Henle W, Fleisher G, Bocker J, Lennette ET, Henle G. Primary Epstein-Barr virus infections in African infants. I. decline of maternal antibodies and time of infection. Int J Cancer (1978) 22:239–43. doi: 10.1002/ijc.2910220304 PubMed DOI

Pope JH, Walters MK, Scott W, Gunz FW. Antibody to Epstein-Barr virus in man in Australia and new Guinea. Int J Cancer (1973) 12:689–98. doi: 10.1002/ijc.2910120316 PubMed DOI

Pender MP. CD8+ T cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis (2012) 2012:189096. doi: 10.1155/2012/189096 PubMed DOI PMC

Balfour HH, Jr., Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis (2013) 208:1286–93. doi: 10.1093/infdis/jit321 PubMed DOI

Balfour HH, Jr., Verghese P. Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load. J Infect Dis (2013) 207:1787–9. doi: 10.1093/infdis/jit096 PubMed DOI PMC

Condon LM, Cederberg LE, Rabinovitch MD, Liebo RV, Go JC, Delaney AS, et al. . Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment. Clin Infect Dis (2014) 59:501–8. doi: 10.1093/cid/ciu342 PubMed DOI

Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M, et al. . Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Intrenat (2006) 56:112–6. doi: 10.1111/j.1440-1827.2006.01936.x PubMed DOI

McKinney CO, Hahn-Holbrook J, Chase-Lansdale PL, Ramey SL, Krohn J, Reed-Vance M, et al. . Racial and ethnic differences in breastfeeding. Pediatrics (2016) 138:e20152388. doi: 10.1542/peds.2015-2388 PubMed DOI PMC

Daud II, Coleman CB, Smith NA, Ogolla S, Simbiri K, Bukusi EA, et al. . Breast milk as a potential source of Epstein-Barr virus transmission among infants living in a malaria-endemic region of Kenya. J Infect Dis (2015) 212:1735–42. doi: 10.1093/infdis/jiv290 PubMed DOI PMC

Lee HJ, Elo IT, McCollum KF, Culhane JF. Racial/ethnic differences in breastfeeding initiation and duration among low-income, inner-city mothers. Soc Sci Q (2009) 90:1251–71. doi: 10.1111/j.1540-6237.2009.00656.x PubMed DOI PMC

Julian BA, Wyatt RJ, Waldo FB, Koopman WJ, Jackson S, Schrohenloher RE, et al. . Immunological studies of IgA nephropathy: familial and racial aspects. Adv Exp Med Biol (1987) 216B:1489–98. PubMed

Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 356:461–73. doi: 10.1098/rstb.2000.0783 PubMed DOI PMC

Evans AS, Niederman JC. Epstein-Barr Virus. In: Evans AS, editor. Viral infections of human - epidemiology and control. 1, 2 ed. Boston, MA: Springer; (1982). p. 253–82.

Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med (2004) 350:1328–37. doi: 10.1056/NEJMra032015 PubMed DOI

Draborg AH, Duus K, Houen G. Epstein-Barr Virus in systemic autoimmune diseases. Clin Dev Immunol (2013) 2013:535738. doi: 10.1155/2013/535738 PubMed DOI PMC

Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. . Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet (2018) 50:699–707. doi: 10.1038/s41588-018-0102-3 PubMed DOI PMC

Fox R. Epstein-Barr Virus and human autoimmune diseases: possibilities and pitfalls. J Virol Methods (1988) 21:19–27. doi: 10.1016/0166-0934(88)90049-3 PubMed DOI

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol (2015) 33:787–821. doi: 10.1146/annurev-immunol-032414-112326 PubMed DOI

Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol (2003) 24:584–48. doi: 10.1016/j.it.2003.09.005 PubMed DOI

Varis J, Rantala I, Pasternack A, Oksa H, Jantti M, Paunu ES, et al. . Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol (1993) 46:607–10. doi: 10.1136/jcp.46.7.607 PubMed DOI PMC

Paizis E, Murphy BF. Serum sickness. In: Roitt IM, Delves PJ, editors. Encyclopedia of immunology. 4, 2 ed. San Diego: Academic Press; (1998). p. 2168–70.

Borok MZ, Nathoo KJ, Gabriel R, Porter KA. Clinicopathological features of Zimbabwean patients with sustained proteinuria. Cent Afr J Med (1997) 43:152–8. PubMed

Liu L, Khan A, Sanchez-Rodriguez E, Zanoni F, Li Y, Steers N, et al. . Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits. Nat Commun (2022) 13:6859. doi: 10.1038/s41467-022-34456-6 PubMed DOI PMC

Hesse J, Ibsen KK, Krabbe S, Uldall P. Prevalence of antibodies to Epstein-Barr virus (EBV) in childhood and adolescence in Denmark. Scand J Infect Dis (1983) 15:335–8. doi: 10.3109/inf.1983.15.issue-4.03 PubMed DOI

Chang JH, Kim DK, Kim HW, Park SY, Yoo TH, Kim BS, et al. . Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transpl (2009) 24:2406–10. doi: 10.1093/ndt/gfp091 PubMed DOI

Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int (2001) 59:823–34. doi: 10.1046/j.1523-1755.2001.059003823.x PubMed DOI

Davin JC. Henoch-Schönlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol (2011) 6:679–89. doi: 10.2215/CJN.06710810 PubMed DOI

Lau KK, Suzuki H, Novak J, Wyatt RJ. Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol (2010) 25:19–26. doi: 10.1007/s00467-009-1230-x PubMed DOI PMC

Meadow SR, Scott DG. Berger Disease: Henoch-Schönlein syndrome without the rash. J Pediatr (1985) 106:27–32. doi: 10.1016/S0022-3476(85)80459-5 PubMed DOI

Novak J, Moldoveanu Z, Renfrow MB, Yanagihara T, Suzuki H, Raska M, et al. . IgA nephropathy and Henoch-Schöenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol (2007) 157:134–8. doi: 10.1159/0000102455 PubMed DOI

Allen AC, Willis FR, Beattie TJ, Feehally J. Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transpl (1998) 13:930–4. doi: 10.1093/ndt/13.4.930 PubMed DOI

Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J. Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep (2019) 4:1717–24. doi: 10.1016/j.ekir.2019.08.015 PubMed DOI PMC

Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. . IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int (2018) 93:700–5. doi: 10.1016/j.kint.2017.10.019 PubMed DOI

Boyd JK, Barratt J. Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next? Kidney Int (2011) 80:8–10. doi: 10.1038/ki.2011.83 PubMed DOI

Kim CJ, Woo YJ, Kook H, Choi YY, Ma JS, Hwang TJ. Henoch-Schönlein purpura nephritis associated with Epstein-Barr virus infection in twins. Pediatr Nephrol (2004) 19:247–8. doi: 10.1007/s00467-003-1387-7 PubMed DOI

Lofters WS, Pineo GF, Luke KH, Yaworsky RG. Henoch-Schönlein purpura occurring in three members of a family. Can Med Assoc J (1973) 109:46–8. PubMed PMC

Karakayali B, Yilmaz S, Cakir D, Gunes PG, Guven S, Islek I. Henoch-Schönlein purpura associated with primary active Epstein-Barr virus infection: a case report. Pan Afr Med J (2017) 27:29. doi: 10.11604/pamj.2017.27.29.10481 PubMed DOI PMC

Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B cell subset of healthy tonsils. J Virol (2000) 74:9964–71. doi: 10.1128/jvi.74.21.9964-9971.2000 PubMed DOI PMC

Brandtzaeg P. Immunobiology of the tonsils and adenoids. In: Mestecky J, Strober W, Russel MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal immunology. 1. Amsterdam: Academic Press; (2015). p. 1985–2016.

Spencer J, Janoff EN, Brandtzaeg P. Mucosal B cells and their function. In: Smith PD, Blumberg RS, MacDonald TT, editors. Principles of mucosal immunology, 2 ed. Boca Raton: CRC Press, Garland Science; (2020). p. 135–50.

Johansen FE, Baekkevold ES, Carlsen HS, Farstad IN, Soler D, Brandtzaeg P. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood (2005) 106:593–600. doi: 10.1182/blood-2004-12-4630 PubMed DOI

Korsrud FR, Brandtzaeg P. Immune systems of human nasopharyngeal and palatine tonsils: histomorphometry of lymphoid components and quantification of immunoglobulin-producing cells in health and disease. Clin Exp Immunol (1980) 39:361–70. PubMed PMC

Bene MC, Faure GC, Hurault de Ligny B, de March AK. Clinical involvement of the tonsillar immune system in IgA nephropathy. Acta Oto-laryngol Suppl (2004) 555:10–4. doi: 10.1080/03655230410003369 PubMed DOI

Egido J, Blasco R, Lozano L, Sancho J, Garcia-Hoyo R. Immunological abnormalities in the tonsils of patients with IgA nephropathy: inversion in the ratio of IgA: IgG bearing lymphocytes and increased polymeric IgA synthesis. Clin Exp Immunol (1984) 57:101–6. PubMed PMC

Harper SJ, Allen AC, Bene MC, Pringle JH, Faure G, Lauder I, et al. . Increased dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ hybridization for J chain mRNA. Clin Exp Immunol (1995) 101:442–8. doi: 10.1111/j.1365-2249.1995.tb03132.x PubMed DOI PMC

Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, Kato M, et al. . IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis (2003) 42:486–96. doi: 10.1016/S0272-6386(03)00743-1 PubMed DOI

Itoh A, Iwase H, Takatani T, Nakamura I, Hayashi M, Oba K, et al. . Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transpl (2003) 18:1108–14. doi: 10.1093/ndt/gfg108 PubMed DOI

Inoue T, Sugiyama H, Kikumoto Y, Fukuoka N, Maeshima Y, Hattori H, et al. . Downregulation of the beta1,3- galactosyltransferase gene in tonsillar b lymphocytes and aberrant lectin bindings to tonsillar IgA as a pathogenesis of IgA nephropathy. Contrib Nephrol (2007) 157:120–4. doi: 10.1159/0000102315 PubMed DOI

Iwanami N, Iwase H, Takahashi N, Kato K, Itoh A, Takatani T, et al. . Similarities between N-glycan glycoform of tonsillar IgA1 and that of aberrant IgA1 abundant in IgA nephropathy patient serum. J Nephrol (2008) 21:118–26. PubMed

Meng H, Ohtake H, Ishida A, Ohta N, Kakehata S, Yamakawa M. IgA production and tonsillar focal infection in IgA nephropathy. J Clin Exp Hematop (2012) 52:161–70. doi: 10.3960/jslrt.52.161 PubMed DOI

Sato M, Hotta O, Tomioka S, Horigome I, Chiba S, Miyazaki M, et al. . Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clin Pract (2003) 93:c137–c45. doi: 10.1159/000070233 PubMed DOI

Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, et al. . Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transpl (2012) 27:1090–7. doi: 10.1093/ndt/gfr403 PubMed DOI

Wang Y, Chen J, Chen Y, Wang L, Lv Y. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol Dial Transpl (2011) 26:1923–31. doi: 10.1093/ndt/gfq674 PubMed DOI

Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int (2004) 65:1135–44. doi: 10.1111/j.1523-1755.2004.00486.x PubMed DOI

Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol (2008) 3:1301–7. doi: 10.2215/CJN.00310108 PubMed DOI PMC

Feehally J, Coppo R, Troyanov S, Bellur SS, Cattran D, Cook T, et al. . Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy. Nephron (2016) 132:15–24. doi: 10.1159/000441852 PubMed DOI

Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, et al. . Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open (2019) 2:e194772. doi: 10.1001/jamanetworkopen.2019.4772 PubMed DOI PMC

Feehally J. Tonsillectomy has no place in the treatment of IgA nephropathy. Kidney Dis (Basel) (2018) 4:160–1.

Kawamura T. Tonsillectomy is a valuable treatment option in IgA nephropathy. Kidney Dis (Basel) (2018) 4:167.